$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
释倍灵国内上市时间
2025-10-19 11:44:20
Check Details
个性化PET4引导治疗可减少霍奇金淋巴瘤患者的放射治疗
2025-10-19 11:44:20
Check Details
释倍灵是医保报销药物吗?
2025-10-19 11:44:20
Check Details
释倍灵用途和效果
2025-10-19 11:44:20
Check Details
Glofitamab对I-IIA级、转化型滤泡性淋巴瘤具有较好的抗肿瘤活性
2025-10-19 11:44:20
Check Details
利妥昔单抗注射液功效与作用
2025-10-19 11:44:20
Check Details
利妥昔单抗注射液进入医保了吗?
2025-10-19 11:44:20
Check Details
利妥昔单抗治疗淋巴瘤多久见效?
2025-10-19 11:44:20
Check Details
利妥昔单抗在医保范围内吗?
2025-10-19 11:44:20
Check Details
利妥昔单抗注射液价格
2025-10-19 11:44:20
Check Details
利妥昔单抗多久打一次?
2025-10-19 11:44:20
Check Details
利妥昔单抗注射液医保可以报销吗?
2025-10-19 11:44:20
Check Details
1
2
...
1259
1260
1261
1262
1263
1264
1265
...
4163
4164
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
2
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
3
Selumetinib and KRAS Mutations: Where the MEK Inhibitor Actually Fits
4
Erdafitinib in Lung Squamous Cell Carcinoma: Indication Boundaries and FGFR Interpretation
5
Daraxonrasib (Rasonque): Chemical Identity and RAS Tri-Complex Mechanism
6
Tamoxifen and Feeling Older: Managing Hot Flashes, Fatigue, and Skin Changes
7
FDA Approves Pembrolizumab for TMB-H Solid Tumors: Threshold ≥13 mut/Mb, KEYNOTE-158 Data
8
Capmatinib for METex14 NSCLC: Test First, Monitor Toxicity
9
Ribociclib Still Allows Recurrence: HR+/HER2- Adjuvant and Advanced Use
10
Tucatinib HER2 TKI: With Trastuzumab + Capecitabine, Diarrhea and Hepatotoxicity Monitoring
11
Pemigatinib for FGFR2-Rearranged Cholangiocarcinoma: Eligibility, Response Limits, Hyperphosphatemia and Ocular Monitoring
12
Cabozantinib with Aspirin: Additive Bleeding Risk, Do Not Stop Cardiac Aspirin Alone, Urgent Warning Signs